New Therapeutic Targets in Rheumatoid Arthritis (Progress in Inflammation Research)

233 Pages·2009·1.92 MB·English

by  Paul-Peter Tak

Progress in Inflammation Research
Series Editor
Prof. Michael J. Parnham PhD
Director of Preclinical Discovery
Centre of Excellence in Macrolide Drug Discovery
GlaxoSmithKline Research Centre Zagreb Ltd.
Prilaz baruna Filipovic´a 29
HR-10000 Zagreb
Croatia
Advisory Board
G. Z. Feuerstein (Wyeth Research, Collegeville, PA, USA)
M. Pairet (Boehringer Ingelheim Pharma KG, Biberach a.d. Riss, Germany)
W. van Eden (Universiteit Utrecht, Utrecht, The Netherlands)
Forthcoming titles:
Inflammatory Cardiomyopathy (DCM) – Pathogenesis and Therapy, H.-P. Schultheiß,
M. Noutsias (Editors), 2009
Occupational Asthma, T. Sigsgaard, D. Heederick (Editors), 2009
Nuclear Receptors and Inflammation, G.Z. Feuerstein, L.P. Freedman, C.K. Glass (Editors),
2009
The Hygiene Hypothesis and Darwinian Medicine, G.A.W. Rook (Editor), 2009
(Already published titles see last page.)
New Therapeutic Targets in
Rheumatoid Arthritis
Paul-Peter Tak
Editor
Birkhäuser
Basel · Boston · Berlin
Editor
Paul-Peter Tak
Division of Clinical Immunology and Rheumatology
EULAR & FOCIS Center of Excellence
Academic Medical Center
University of Amsterdam
Meibergdreef 9, Room F4-218
1105 AZ Amsterdam
The Netherlands
Library of Congress Control Number: 2009921933
Bibliographic information published by Die Deutsche Bibliothek
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie;
detailed bibliographic data is available in the internet at http://dnb.ddb.de
ISBN 978-3-7643-8237-7 Birkhäuser Verlag AG, Basel – Boston – Berlin
The publisher and editor can give no guarantee for the information on drug dosage and administration contained in this
publication. The respective user must check its accuracy by consulting other sources of reference in each individual case.
The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that
they are exempt from the relevant protective laws and regulations or free for general use.
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned,
specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on micro-
films or in other ways, and storage in data banks. For any kind of use, permission of the copyright owner must
be obtained.
© 2009 Birkhäuser Verlag AG
Basel · Boston · Berlin
P.O. Box 133, CH-4010 Basel, Switzerland
Part of Springer Science+Business Media
Printed on acid-free paper produced from chlorine-free pulp. TCF (cid:99)
Cover design: Markus Etterich, Basel
Cover illustration: see page 68. With friendly permission of Wim B. van den Berg.
Printed in Germany
ISBN 978-3-7643-8237-7 e-ISBN 978-3-7643-8238-4
9 8 7 6 5 4 3 2 1 www.birkhauser.ch
Contents
List of contributors ................................................................. vii
Preface .............................................................................. xi
Edward M. Vital, Shouvik Dass and Paul Emery
B cell targets in rheumatoid arthritis ............................................... 1
Eric M. Ruderman and Richard M. Pope
Co-stimulatory pathways in the therapy of rheumatoid arthritis ................. 27
Yoshiyuki Ohsugi and Tadamitsu Kishimoto
Immunobiology of IL-6 – Tocilizumab (humanized anti-IL-6 receptor
antibody) for the treatment of rheumatoid arthritis .............................. 45
Wim B. van den Berg, Leo A. B. Joosten and Fons A. J. van de Loo
Role of IL-1 in erosive arthritis, lessons from animal models ..................... 59
Jagtar Nijar Singh and Iain B. McInnes
Interleukin-15 ....................................................................... 75
Pierre Miossec, Ling Toh and Saloua Zrioual
IL-17 and Th17 cells, key players in arthritis ...................................... 89
Charles A. Dinarello
Role of IL-18 in inflammatory diseases ............................................ 103
Zoltán Szekanecz and Alisa E. Koch
Chemokines and chemokine receptors ............................................ 129
Jean-Marc Waldburger and Gary S. Firestein
Signaling pathways in rheumatoid arthritis ........................................ 155
DCoalnipte Jn.Sts. Sirinathsinghji and Ray G. Hill
Theresa C. Barnes and Robert J. Moots
Targeting oncostatin M in the treatment of rheumatoid arthritis ................ 181
Lars C. Huber, Astrid Jüngel and Steffen Gay
Targeting the epigenetic modifications of synovial cells .......................... 193
Edward C. Keystone
Perspectives in targeted therapy ................................................... 207
Index ................................................................................ 221
vi
List of contributors
Theresa C. Barnes, Division of Inflammation, School of Clinical Sciences, University
of Liverpool, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK
Shouvik Dass, Section of Musculoskeletal Disease, Leeds Institute of Molecular
Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK
Charles A. Dinarello, Department of Medicine, Division of Infectious Diseases, Uni-
versity of Colorado Denver, 12700 East 19th Ave, B168, Aurora, CO 80045, USA;
e-mail: [email protected]
Paul Emery, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medi-
cine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK;
e-mail: [email protected]
Gary S. Firestein, University of California, San Diego, Department of Medicine,
Biomedical Science Bldg. RM 5096, 9500 Gilman Drive, La Jolla, CA 92093-0656,
USA; e-mail: [email protected]
Steffen Gay, Center of Experimental Rheumatology, Department of Rheumatology,
University Hospital of Zürich, Zürich Center of Integrative Human Physiology
(ZIHP), Gloriastrasse 25, 8091 Zürich, Switzerland
Lars C. Huber, Center of Experimental Rheumatology, Department of Rheumatol-
ogy, University Hospital of Zürich, Zürich Center of Integrative Human Physiology
(ZIHP), Gloriastrasse 25, 8091 Zürich, Switzerland; e-mail: [email protected]
Leo A.B. Joosten, Rheumatology Research & Advanced Therapeutics, Department
of Rheumatology, Radboud University Nijmegen Medical Centre, Geert Groote-
plein 28, 6525 GA, Nijmegen, The Netherlands
vii
List of contributors
Astrid Jüngel, Center of Experimental Rheumatology, Department of Rheumatol-
ogy, University Hospital of Zürich, Zürich Center of Integrative Human Physiology
(ZIHP), Gloriastrasse 25, 8091 Zürich, Switzerland
Edward C. Keystone, University of Toronto, Division of Rheumatology, Rebecca
MacDonald Centre for Arthritis and Autoimmune Diseases, 60 Murray Street,
Toronto, Ontario M5T 3L9, Canada; e-mail: [email protected]
Tadamitsu Kishimoto, Graduate School of Frontier Bioscience, Osaka University,
Osaka 565-0871, Japan; e-mail: [email protected]
Alisa E. Koch, Veterans’ Administration, Ann Arbor Healthcare System, Ann Arbor,
MI, USA and University of Michigan Health System, Department of Internal Medi-
cine, Division of Rheumatology, Ann Arbor, MI, USA
Iain B. McInnes, Centre for Rheumatic Diseases, Division of Immunology, Infection
and Inflammation, University of Glasgow, 10 Alexandra Parade, Glasgow Royal
Infirmary, Glasgow G312ER, UK; e-mail: [email protected]
Pierre Miossec, Department of Immunology and Rheumatology, Hôpital Edouard
Herriot, 69437 Lyon Cedex 03, France; e-mail: [email protected]
Robert J. Moots, Division of Inflammation, School of Clinical Sciences, University
of Liverpool, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK;
e-mail: [email protected]
Yoshiyuki Ohsugi, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan;
e-mail: [email protected]
Richard M. Pope, Division of Rheumatology, Northwestern University Feinberg
School of Medicine, McGaw M300, 240 E. Huron Street, Chicago, IL 60611,
USA
Eric M. Ruderman, Division of Rheumatology, Northwestern University Feinberg
School of Medicine, McGaw M300, 240 E. Huron Street, Chicago, IL 60611,
USA
Jagtar Nijar Singh, Centre for Rheumatic Diseases, Division of Immunology, Infec-
tion and Inflammation, University of Glasgow, 10 Alexandra Parade, Glasgow
Royal Infirmary, Glasgow G312ER, UK
viii
List of contributors
Zoltán Szekanecz, Department of Rheumatology, Institute of Medicine, Univer-
sity of Debrecen Medical and Health Science Center, 22 Móricz street, Debrecen,
H-4004, Hungary; e-mail: [email protected]
Ling Toh, Department of Immunology and Rheumatology, Hôpital Edouard Her-
riot, 69437 Lyon Cedex 03, France
Fons A.J. van de Loo, Rheumatology Research & Advanced Therapeutics, Depart-
ment of Rheumatology, Radboud University Nijmegen Medical Centre, Geert
Grooteplein 28, 6525 GA, Nijmegen, The Netherlands
Wim B. van den Berg, Rheumatology Research & Advanced Therapeutics, Depart-
ment of Rheumatology, Radboud University Nijmegen Medical Centre, Geert
Grooteplein 28, 6525 GA, Nijmegen, The Netherlands;
e-mail: [email protected]
Edward M. Vital, Section of Musculoskeletal Disease, Leeds Institute of Molecular
Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK
Jean-Marc Waldburger, University of Geneva, Centre médical universitaire, 1 rue
Michel Servet, 1211 Geneva, Switzerland; e-mail: [email protected]
Saloua Zrioual, Department of Immunology and Rheumatology, Hôpital Edouard
Herriot, 69437 Lyon Cedex 03, France
ix